Axogen (AXGN) Insider Alan Levine Buys 4,392 Shares

Alan Levine purchased 4,392 shares of Axogen, Inc. (NasdaqCM: AXGN) on June 24, 2026. This insider buying move did not involve a pre-planned trading program, indicating potential confidence in the company's future prospects. The transaction was recorded at a time when Axogen's stock was trading around $44.49 per share.

Insider Buying and Selling at Axogen, Inc.

Alan Levine wasn't the only one adding to his position in Axogen. On the same day, several other insiders, including Kathy Johnson Weiler, Joseph Tyndall, Paul Thomas, Amy McBride Wendell, William Burke, and John Johnson, each purchased 4,392 shares. These transactions suggest a coordinated belief in the company's potential.

Other Institutional Activity in Axogen

Institutional investors have also been active in Axogen. First Light Asset Management, LLC reduced its holdings by 1,230,558 shares, leaving it with 4,002,768 shares valued at about $132.6 million. BlackRock, Inc. increased its position by 151,414 shares to 3,870,851 shares, worth approximately $128.2 million. Morgan Stanley added 536,112 shares, growing its stake by 20.7% to 3,122,982 shares valued at $103.5 million. Vanguard Capital Management LLC opened a new position with 2,291,563 shares valued at around $75.9 million. Arrowmark Colorado Holdings LLC boosted its holdings by 441,157 shares, ending with 1,915,439 shares worth about $63.5 million.

Axogen, Inc. Stock Up 0.6%

Shares of Axogen, Inc. traded near $44.49 on Saturday. The company, which specializes in medical devices for nerve repair, has a market capitalization of $2.37 billion. It carries a forward P/E ratio of 61.08 and a beta of 1.118, indicating moderate market volatility. The stock has seen a 52-week low of $10.20 and a high of $46.00, with a 50-day moving average of $41.31 and a 200-day moving average of $30.96. Axogen maintains a strong liquidity position with a current ratio of 7.101 and a quick ratio of 4.994, alongside a low debt-to-equity ratio of 8.432.

Recent Earnings

Axogen reported revenue of $238.1 million, reflecting a growth rate of 26.6%. However, the company posted a net margin of -13.21% and a return on equity of -17.96%, indicating challenges in profitability. The next earnings report is expected on August 4, 2026.

Analysts Set New Price Targets

Several analysts have maintained a 'buy' rating for Axogen. On April 29, 2026, firms like Canaccord Genuity, Citizens, Wells Fargo, and HC Wainwright & Co. affirmed their 'buy' ratings with price targets around $50. Lake Street also maintained a 'buy' with a similar target on April 23, 2026. The consensus target price is approximately $50.78, based on nine analyst opinions.

About Axogen, Inc.

Axogen, Inc., based in Alachua, Florida, develops and markets products for peripheral nerve regeneration and repair. The company's offerings include the Avance Nerve Graft and Axoguard products, which are used in surgical repair and protection of peripheral nerves. Led by CEO Lindsey Hartley, Axogen operates in the healthcare sector, specifically within the medical devices industry, employing 622 people.

Bottom Line

Insider buying activity at Axogen, Inc. reflects potential confidence in its future. The company's recent financial performance shows strong revenue growth but challenges in profitability. Investors and analysts continue to closely watch Axogen, with many maintaining 'buy' ratings and optimistic price targets. As always, it's important to remember that insider transactions are reported after they occur and may not reflect current positions.